SIX Soins de santé Drug Manufacturers - Specialty & Generic PPGN.SW

PolyPeptide Group AG

$ 39.35 5.50 %

PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.

CEO: Juan Jose Gonzalez - https://www.polypeptide.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

-

Recommandation

-

DCF

$ -37.84

Loading data...

PPGN.SW vs S&P500

Loading data...

No data available.

Quick ratio

0.91

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

-66.69

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.59

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-6.30 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

1.02 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

9.43

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.38

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.92

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
3.03 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.40 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.16 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.